Cell cycle proteins as promising targets in cancer therapy
T Otto, P Sicinski - Nature Reviews Cancer, 2017 - nature.com
Cancer is characterized by uncontrolled tumour cell proliferation resulting from aberrant
activity of various cell cycle proteins. Therefore, cell cycle regulators are considered …
activity of various cell cycle proteins. Therefore, cell cycle regulators are considered …
Unravelling the biology of SCLC: implications for therapy
Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
We characterized the mutational landscape of melanoma, the form of skin cancer with the
highest mortality rate, by sequencing the exomes of 147 melanomas. Sun-exposed …
highest mortality rate, by sequencing the exomes of 147 melanomas. Sun-exposed …
The aurora kinases in cell cycle and leukemia
B Goldenson, JD Crispino - Oncogene, 2015 - nature.com
The Aurora kinases, which include Aurora A (AURKA), Aurora B (AURKB) and Aurora C
(AURKC), are serine/threonine kinases required for the control of mitosis (AURKA and …
(AURKC), are serine/threonine kinases required for the control of mitosis (AURKA and …
Aurora kinase inhibitors: current status and outlook
V Bavetsias, S Linardopoulos - Frontiers in oncology, 2015 - frontiersin.org
The Aurora kinase family comprises of cell cycle-regulated serine/threonine kinases
important for mitosis. Their activity and protein expression are cell cycle regulated, peaking …
important for mitosis. Their activity and protein expression are cell cycle regulated, peaking …
Aurora‐A kinase: a potent oncogene and target for cancer therapy
M Yan, C Wang, B He, M Yang, M Tong… - Medicinal research …, 2016 - Wiley Online Library
The Aurora kinase family is comprised of three serine/threonine kinases, Aurora‐A, Aurora‐
B, and Aurora‐C. Among these, Aurora‐A and Aurora‐B play central roles in mitosis …
B, and Aurora‐C. Among these, Aurora‐A and Aurora‐B play central roles in mitosis …
[HTML][HTML] Small cell lung cancer: novel treatments beyond immunotherapy
JJ Meijer, A Leonetti, G Airò, M Tiseo, C Rolfo… - Seminars in cancer …, 2022 - Elsevier
Small cell lung cancer (SCLC) arises in peribronchial locations and infiltrates the bronchial
submucosa, including about 15% of lung cancer cases. Despite decades of research, the …
submucosa, including about 15% of lung cancer cases. Despite decades of research, the …
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and …
B Melichar, A Adenis, AC Lockhart, J Bennouna… - The Lancet …, 2015 - thelancet.com
Background Alisertib is an investigational, oral, selective inhibitor of aurora kinase A. We
aimed to investigate the safety and activity of single-agent alisertib in patients with …
aimed to investigate the safety and activity of single-agent alisertib in patients with …
Drugging MYCN through an allosteric transition in Aurora kinase A
WC Gustafson, JG Meyerowitz, EA Nekritz, J Chen… - Cancer cell, 2014 - cell.com
MYC proteins are major drivers of cancer yet are considered undruggable because their
DNA binding domains are composed of two extended alpha helices with no apparent …
DNA binding domains are composed of two extended alpha helices with no apparent …
Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma
M Brockmann, E Poon, T Berry, A Carstensen… - Cancer cell, 2013 - cell.com
Amplification of MYCN is a driver mutation in a subset of human neuroendocrine tumors,
including neuroblastoma. No small molecules that target N-Myc, the protein encoded by …
including neuroblastoma. No small molecules that target N-Myc, the protein encoded by …